Last reviewed · How we verify
NCT05343117
Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC
trial testing Palbociclib based-therapy as initial endocrine therapy in Hormone Receptor Positive Advanced Breast Cancer in 400 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 December 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 1 June 2024 |
| Sites | 9 locations across China |
Drugs / interventions tested
- Palbociclib based-therapy as initial endocrine therapy — full drug profile →
- Palbociclib based-therapy after chemotherapy — full drug profile →
Conditions studied
- Hormone Receptor Positive Advanced Breast Cancer — all drugs for Hormone Receptor Positive Advanced Breast Cancer →
Sponsor
Chinese Academy of Medical Sciences — full company profile →
Who can join
18 and older, female only, with Hormone Receptor Positive Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multi-center non-interventional observational study led by the Cancer Hospital Chinese Academy of Medical Sciences to compare the effectiveness of palbociclib based-therapy as initial endocrine therapy versus palbociclib based-therapy after chemotherapy for HR+/HER2- advanced breast cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05343117
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Chinese Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
- NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
- NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
- NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
- NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05343117 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
- Last refreshed: 26 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05343117.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing